SynthesisInternational journal of impotence research2026
Functional outcomes of glansectomy to treat localised penile cancer: a systematic review.
Synthesis in International journal of impotence research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Advanced genital reconstructive surgery: evolving techniques, expanding indications and future directions.International journal of impotence research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Glansectomy with or without a neoglans reconstruction is commonly performed for invasive penile cancer confined to the glans penis. The aim of penile-preserving procedures is to maintain sexual and urinary function without compromising oncological outcomes. A systematic review was performed to evaluate the functional outcomes following glansectomy. Overall, 14 studies which included 327 glansectomy procedures were analysed. At a mean follow-up of 40.7 (range, 13-52) months, the recurrence rate was 9.1% (0-25%) and the disease-specific survival rate was 87.5-100%. Partial graft loss and meatal stenosis occurred in 6.1% (0-17.6%) and 8.1% (0-14.3%) respectively. 91.1% (50-100%) had preserved erectile function and 62.5% (33.3-100%) were sexually active. 75.6% (66.7-100%) of patients were voiding whilst standing up and 83.7% (63.6-91.2%) had maintained glans sensation. Satisfaction with the overall appearance was achieved in 86.3% (68.2-100%). The reporting of functional outcomes was heterogenous with a limitation that there are no standardised guidelines on the assessment of functional outcomes following glansectomy. Further research should focus on identifying appropriate tools for reporting functional outcomes following glansectomy and standardising reporting.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.